close crossing 52-week high zond

Glenmark Pharmaceuticals Ltd's stock is currently trading at ₹1944, with a market cap of ₹54,219.24 crore. - Financial Performance: The company reported a 72.2% jump in consolidated profit after tax (PAT) to ₹610.43 crore for Q2 FY26, driven by its licensing deal with AbbVie for ISB 2001. Revenue from operations stood at ₹6,046.87 crore, up from ₹3,433.8 crore in Q2 FY25. - US FDA Clearance: Glenmark received the Establishment Inspection Report (EIR) from the US FDA for its Monroe, North Carolina facility, with a Voluntary Action Indicated (VAI) status, allowing commercial manufacturing to restart. - Technical Outlook: The stock has shown a mildly bullish trend, with a 50-day EMA crossover indicating potential upside Disclaimer: Investing and Trading in Stock Market is risky activity. Always trade with a stop loss. Do not Trade's invest by taking loan and trade only with the money that you can afford to risk. Do not put your entire capital in one single Trade.